Notal Vision Inc. released two clinical reports it said prove the feasibility and efficacy of its patient-operated, home-based optical coherence tomography (OCT) device for monitoring wet age-related macular degeneration (AMD). This comes in the wake of a 2021 report that concluded patient operation of the Notal Vision Home OCT (NVHO) and its machine learning algorithm were generally on par with human experts evaluating retinal fluid and fluid volume in patients with AMD.
Illumina Inc.’s acquisition of Grail Inc., of Menlo Park, Calif., may or may not prove to be a case of jumping the regulatory gun, but the move to date has not racked up significant financial penalties for the company. That may soon change per a statement by the European Commission, which said that Illumina may find itself on the receiving end of “hefty fines,” a statement made by EC executive vice president Margrethe Vestager.
The effects of U.S. Supreme Court case law on patents are well demonstrated, but the latest victims of patent jurisprudence are directed toward a critical need for desperately ill patients. The Court of Appeals for the Federal Circuit ruled that several claims found in three patents licensed to Caredx Inc., of Brisbane, Calif., are ineligible due to a purported lack of inventiveness under Section 101 of the Patent Act, an outcome that sustains what some believe is a trend in case law that is hostile toward diagnostic patents in the U.S.
Pillar Biosciences LLC hopes to build a stronger foundation for its multi-cancer in vitro diagnostic, Oncoreveal Dx. The company filed a supplemental application for U.S. FDA premarket approval of eight additional types of cancer, which the agency accepted for review. The assay received FDA premarket approval for use in non-small cell lung cancer (NSCLC) and colon cancer in August 2021.
Oxford Science Enterprises, an independent investor specializing in building companies through its relationship with the U.K.’s University of Oxford, has raised a further £250 million (US$300 million) to translate academic research into commercial products and businesses.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Beckman Coulter, Danaher, Electromedical Technologies, Guided Therapeutics, Istar, Nanostics, Scopio, Spinal Elements.
The value of med-tech mergers and acquisitions in the first half of 2022 are at a five-year high and about 84% ahead of last year. The volume of M&As fell significantly in the second quarter, however, with only 104 completed that were worth $46.5 billion, 27.8% less than the first quarter’s value of $64.7 billion. Regardless, M&As in the first half of 2022 are towering over each of the four prior years’ first two quarters, with a total completed of 276 worth $110.9 billion.
RSS
